NOW READING · PK READOUT
CJC-1295 Half-Life: Why Albumin Conjugation Extends Duration
The estimated 5.8-8.1 day half-life of the DAC variant is the single property the chemistry exists to produce. Here is where that number comes from, and why the no-DAC form never reaches it.
The CJC-1295 Half-Life Figure and Where It Comes From
The CJC-1295 half-life that matters is the DAC variant's: an estimated 5.8 to 8.1 days in healthy adults [1]. That number is not a model extrapolation — it comes from the human pharmacokinetic study that dosed adults with single and multiple subcutaneous doses of 30 or 60 micrograms/kg and tracked GH and IGF-1 for weeks. Mean GH stayed 2- to 10-fold above baseline for six days or more; IGF-1 stayed elevated nine to eleven days after one dose, and up to 28 days after multiple doses [1].
A half-life measured in days, for a peptide, is the anomaly the rest of this page explains. Free peptides of this size clear in minutes. The 5.8-8.1 day figure is the direct, measured consequence of the albumin-bioconjugation chemistry.
Why Albumin Conjugation Extends Duration
Albumin conjugation extends duration because it changes what the kidney sees. The DAC variant's maleimidopropionyl linker covalently binds the Cys34 thiol of serum albumin, so the active circulating species becomes a roughly 66 kDa peptide-albumin complex rather than a small free peptide. Serum albumin has a multi-week half-life of its own; tethering the analog to it drags the analog's residence toward albumin's, which is exactly what the 5.8-8.1 day figure reflects [1].
The four protease-resistant substitutions do the complementary job. Without them, dipeptidylpeptidase-IV would cleave the peptide before albumin binding could matter; the D-Ala2 substitution alone markedly increases the half-life and potency of GHRH(1-29) by blocking that cleavage [9]. Stability plus the albumin tether together produce the multi-day duration.
How the No-DAC Form Compares
The no-DAC form never reaches the DAC half-life because it lacks the albumin tether entirely. Modified GRF 1-29 keeps the four substitutions, so it resists DPP-IV better than native GHRH, but it stays a small free peptide that the kidney clears on a minutes-to-hours timescale. The substitutions buy stability, not the multi-day residence — that requires the DAC conjugation.
This is why the CJC-1295 DAC vs no-DAC distinction is fundamentally a half-life distinction. The estimated half-life of the DAC variant is the property that defines it [1]; strip the DAC moiety and the duration collapses back toward that of the underlying GHRH fragment. The earliest rodent work already showed the conjugate detectable beyond 72 hours where an unconjugated peptide would have vanished [2].
From Rodent Plasma to Human Weeks
The duration claim was built in stages. The first evidence was the rat screen: the lead albumin bioconjugate was detectable in plasma beyond 72 hours, where an unconjugated hGRF(1-29) peptide would have been cleared long before, and it delivered a 4-fold increase in GH area-under-the-curve over the unconjugated control [2]. Detectability past three days in a rodent was the first sign the albumin tether was working as designed.
The human study then put a number on it. Tracking GH and IGF-1 in healthy adults after single and multiple subcutaneous doses, it estimated the half-life at 5.8 to 8.1 days and showed IGF-1 holding above baseline up to 28 days after multiple doses [1]. The progression from 'detectable past 72 hours in rats' to 'half-life of nearly a week in humans' is the empirical spine of the half-life claim — measured, not modeled.
What the Long Half-Life Means for Exposure
A multi-day half-life means exposure persists for days after a single dose — the GH and IGF-1 elevations measured in the human study were not transient spikes but sustained shifts spanning more than a week [1]. In the GHRH-knockout mouse, this duration was sufficient for a once-every-24-hours schedule to fully normalize growth, while spacing doses to 48 or 72 hours was progressively less effective [4].
The long duration is also the basis for caution. Because a single administration sustains GH/IGF-1 elevation for days, any concern tied to sustained axis stimulation — fluid retention, insulin-sensitivity effects, the IGF-1/cancer epidemiology — applies over that whole window, not just at a peak. That is a different risk profile from a short-acting secretagogue, where exposure ends quickly. CJC-1295 remains unapproved, no long-term human exposure data exist, and the molecule is prohibited at all times in sport under WADA Section S2.